Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Perry Renshaw
Serotonin and creatine are processed separately in the brain, and deficits in these brain biochemicals lead to distinct clinical problems. Therefore, investigators believe that treatment with a combination therapy, which could correct both deficits, would have a synergistic effect in the treatment of hypoxia-related depression and possibly other forms of treatment-resistant depression. Thus, investigators propose to investigate antidepressant efficacy of dietary 5-hydroxytryptophan (5-HTP) and creatine, as a means to restore the brain neurotransmitter and metabolic imbalances linked to chronic hypoxia caused by high altitude residence.
Age
18–64
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Female gender, ages 18-64 years inclusive
Current diagnosis of Major Depressive Disorder identified by the SCID-5-CT
Current HAM-D17 score of \> 15
Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks
You may not be if
Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-5-CT
History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease
Diabetes type I or II
Colitis or diverticulitis
History of pulmonary disease
History of fibromyalgia, lupus, eosinophilia myalgia syndrome, dermatomyositis, polymyositis, rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, ankylosing spondylitis, or other related rheumatological condition
Seizure disorder
Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale
Current treatment with an antipsychotic, mood stabilizer, or non-SSRI antidepressant
Positive pregnancy test
Previous diagnosis of serotonin syndrome
Use of any excluded drugs or medications including serotonergic drugs or medications